Skip to main
  1. Stocks
  2. Cencora Inc
  3. Forecast
COR

Cencora Inc (COR) Stock Forecast & Price Target

Cencora Inc (COR) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 54%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Cencora is attractive because its dominant role in a highly concentrated U.S. pharmaceutical wholesale market, alongside McKesson and Cardinal Health, supports durable pricing power, stable volumes, and resilient cash generation even amid volatility. Its specialty platform is a key growth engine, with more than 100 new oncology molecules through 2030, GLP-1-driven growth, and accelerated biosimilar conversion helping drive continued EBIT expansion, while manufacturer services and World Courier add higher-margin, value-chain exposure. The 2021 Alliance Healthcare purchase broadened its international footprint, and disciplined cost management, digital investment, and a conservative FY27 guide with upside potential reinforce a favorable long-term fundamental outlook.

Bears say

Cencora is facing a weaker fundamental setup because management guided Pharma segment EBIT growth of 2-4%, below its long-term range, while FX and Walgreens non-prime volume loss suggest near-term operating headwinds. The investment case is further pressured by a potential slowdown in prescription-drug volumes and pricing, since the business depends on a healthy end-market environment to absorb its heavy fixed-cost infrastructure and support cash flow. Its 2021 Alliance Healthcare acquisition and World Courier expansion add international exposure, but Europe’s centralized healthcare systems and government-controlled pricing, plus working-capital demands and competitive pressure in MWI Animal Health, could keep growth and capital generation subdued.

Cencora Inc (COR) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 54% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cencora Inc and is not a guaranteed prediction by Public.com or investment advice.

Cencora Inc (COR) Analyst Forecast & Price Prediction

Get the latest Cencora Inc (COR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cencora Inc (COR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cencora Inc (COR) Forecast

Analysts have given Cencora Inc (COR) a Buy based on their latest research and market trends.

According to 13 analysts, Cencora Inc (COR) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $381.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $381.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cencora Inc (COR)


Cencora Inc (COR) Analyst Forecast & Price Prediction

Get the latest Cencora Inc (COR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cencora Inc (COR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover COR stock data and trends